comparemela.com

Latest Breaking News On - Asco gu - Page 1 : comparemela.com

Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in Untreated RCC

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Danielj georgeEuropean medicines agencyDuke cancer institutePhase 3b checkmate 8y8 study nct03873402Dvanced renal cell carcinomaAsco gu

Dr Kyriakopoulos on the Initial Activity and Safety of Masofaniten Plus Enzalutamide in mCRPC

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.

United statesUniversity of wisconsin school medicinePublic healthDepartment of medicineDivision of hematologyChristos kyriakopoulosMedical oncologyPalliative careWisconsin schoolCancers symposiumProstate cancerAsco gu

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

German cancer consortium clinical communication platformGerman cancer consortiumClinical communication platformRenal cell carcinomaMorphologic typeTumor stageAsco gu

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Perez valderramaMichiels vanBristol myers squibbAstellas pharmaGilead sciencesCancers symposiumDer heijdenEnfortumab vedotinAsco guGenitourinary cancers symposiumEv 302Keynote a39 trialMichiels van der heijdenNetherlands cancer instituteSubgroup analysisUrothelial carcinoma

Keytruda Side Effects: If Something Doesn t Feel Right … Call

Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said.

Cancer research of the national instituteCancers symposiumBladder cancer sectionGenitourinary malignancies branchBladder cancerGenitourinary tumors multidisciplinary clinicCancer researchNational cancer instituteKeytruda has received nearlyAsco gu

vimarsana © 2020. All Rights Reserved.